W - Meridian Bioscience: Benefiting From A Prolonged Pandemic

• Meridian could expand its testing supply windfall in 2021, as the world grapples with containing mutations of the COVID-19 virus.
• Balance sheet safety, profit margins, revenue growth, and current valuations are better than industry average.
• A large short interest position and a number of analysts may be incorrectly banking on business growth to slip, assuming the coronavirus quickly disappears in the spring.
• The equity name represents a sound, risk-adjusted idea to speculate on and/or hedge a lingering pandemic during 2021.

For further details see: